Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.

• Päätekijät: Dae Hyun Kim (Tekijä), Hye Jin Chung (Tekijä), Joachim Bleys (Tekijä), Reza F Ghohestani (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Public Library of Science (PLoS), 2009-01-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

BACKGROUND: High cost, poor compliance, and systemic toxicity have limited the use of pentavalent antimony compounds (SbV), the treatment of choice for cutaneous leishmaniasis (CL). Paromomycin (PR) has been developed as an alternative to SbV, but existing data are conflicting. METHODOLOGY/PRINCIPAL...